The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Merck KGaA
 
Employment - EMD Serono
Retrospective analysis of overall survival (OS) by subsequent therapy in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving irinotecan ± cetuximab in the EPIC study.
 
Alberto F. Sobrero
Consulting or Advisory Role - Amgen; Bayer; Celgene; Merck Serono; Roche; Sanofi; SERVIER
Speakers' Bureau - amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; celgene; Lilly; Merck Serono; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche; Takeda
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Merck Serono; Roche
Consulting or Advisory Role - Bayer; Merck Serono; Pfizer; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche
 
Cathy Eng
Honoraria - Bayer; Celgene; Roche; Sirtex Medical
Consulting or Advisory Role - Bayer Schering Pharma; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Advaxis; Forty Seven; Genentech/Roche; Keryx
Travel, Accommodations, Expenses - Bayer; Genentech/Roche; Sirtex Medical
 
Werner Scheithauer
No Relationships to Disclose
 
Gary William Middleton
No Relationships to Disclose
 
Wen-Feng Chen
No Relationships to Disclose
 
Regina Esser
Employment - Merck KGaA
Stock and Other Ownership Interests - Merck KGaA
 
Johannes Nippgen
No Relationships to Disclose
 
Howard A. Burris
Employment - HCA Healthcare
Leadership - HCA Healthcare
Stock and Other Ownership Interests - HCA Healthcare
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); FORMA Therapeutics (Inst); Janssen (Inst); MedImmune (Inst); Mersana (Inst); Novartis (Inst); Roche/Genentech (Inst); TG Therapeutics (Inst)
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celldex (Inst); CicloMed (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Harpoon therapeutics (Inst); Immunocore (Inst); Incyte (Inst); Janssen (Inst); Jiangsu Hengrui Medicine (Inst); Jounce Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); OncoMed (Inst); Pfizer (Inst); PTC Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); TG Therapeutics (Inst); Valent Technologies (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Novartis